These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3139413)

  • 1. Long-term efficacy of oral encainide in frequent and repetitive ventricular arrhythmias.
    Bongiorni MG; Levorato D; Arlotta C; Paperini L; Contini C
    Eur Heart J; 1988 Jul; 9(7):765-76. PubMed ID: 3139413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of frequent ventricular arrhythmia with encainide: assessment using serial ambulatory electrocardiograms, intracardiac electrophysiologic studies, treadmill exercise tests, and radionuclide cineangiographic studies.
    DiBianco R; Fletcher RD; Cohen AI; Gottdiener JS; Singh SN; Katz RJ; Bates HR; Sauerbrunn B
    Circulation; 1982 Jun; 65(6):1134-47. PubMed ID: 6804110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-arrhythmia effect of long-term encainide in chronic ventricular extrasystole].
    Dumoulin P; Jaillon P; Kher A; Poirier JM; Cheymol G; Valty J; Flammang D; Coumel P; Medvedowsky JL; Barnay C
    Arch Mal Coeur Vaiss; 1985 Oct; 78 Spec No():105-9. PubMed ID: 2420299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics.
    Roden DM; Reele SB; Higgins SB; Mayol RF; Gammans RE; Oates JA; Woosley RL
    N Engl J Med; 1980 Apr; 302(16):877-82. PubMed ID: 6767186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to encainide of refractory ventricular tachycardia: clinical application of assays for parent drug and metabolites.
    Anderson JL; Stewart JR; Johnson TA; Lutz JR; Pitt B
    J Cardiovasc Pharmacol; 1982; 4(5):812-9. PubMed ID: 6182414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophysiologic and electrocardiographic effects, efficacy and safety of encainide in malignant ventricular arrhythmias associated with coronary artery disease.
    Weintraub AR; Manolis AS; Estes NA
    Am J Cardiol; 1990 Oct; 66(12):947-53. PubMed ID: 2121017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible contribution of encainide metabolites to the long-term antiarrhythmic efficacy of encainide.
    Winkle RA; Peters F; Kates RE; Harrison DC
    Am J Cardiol; 1983 Apr; 51(7):1182-8. PubMed ID: 6404150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectrum of antiarrhythmic response to encainide.
    Duff HJ; Roden DM; Carey EL; Wang T; Primm RK; Woosley RL
    Am J Cardiol; 1985 Nov; 56(13):887-91. PubMed ID: 3933319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
    Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH
    Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Encainide and flecainide: are they interchangeable?
    Saini V; Podrid PJ; Slater W; Lown B
    Am Heart J; 1989 Jun; 117(6):1253-8. PubMed ID: 2499169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of oral encainide in the treatment of chronic ventricular ectopic activity: relationship to plasma concentrations--a French multicenter trial.
    Dumoulin P; Jaillon P; Kher A; Poirier JM; Cheymol G; Valty J; Flammang D; Coumel P; Medvedowsky JL; Barnay C
    Am Heart J; 1985 Sep; 110(3):575-81. PubMed ID: 2412428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant ventricular tachyarrhythmias associated with the use of encainide.
    Winkle RA; Mason JW; Griffin JC; Ross D
    Am Heart J; 1981 Nov; 102(5):857-64. PubMed ID: 6795909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias.
    Winkle RA; Peters F; Kates RE; Tucker C; Harrison DC
    Circulation; 1981 Aug; 64(2):290-6. PubMed ID: 6788400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia.
    Mason JW; Peters FA
    Circulation; 1981 Mar; 63(3):670-5. PubMed ID: 6780234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of incessant supraventricular tachycardia by intravenous and oral encainide.
    Brugada P; Abdollah H; Wellens HJ
    J Am Coll Cardiol; 1984 Dec; 4(6):1255-60. PubMed ID: 6438205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encainide for refractory ventricular tachyarrhythmia.
    Chesnie B; Podrid P; Lown B; Raeder E
    Am J Cardiol; 1983 Sep; 52(5):495-500. PubMed ID: 6193701
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative study of encainide and disopyramide in chronic ventricular arrhythmias: a double-blind placebo-controlled crossover study.
    Caron JF; Libersa CC; Kher AR; Kacet S; Wanszelbaum H; Dupuis BA; Poirier JM; Lekieffre JP
    J Am Coll Cardiol; 1985 Jun; 5(6):1457-63. PubMed ID: 2582017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
    Roden DM; Lee JT; Woosley RL; Echt DS
    Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of encainide in supraventricular arrhythmias.
    Pool PE
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():573-7. PubMed ID: 2125835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Encainide in lethal ventricular arrhythmias evaluated by electrophysiologic testing and decrease in symptoms.
    Horowitz LN
    Am J Cardiol; 1986 Aug; 58(5):83C-86C. PubMed ID: 3092624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.